Bosutinib is a dual Src/Abl inhibitor with IC50s of 1.2 nM and 1 nM, respectively.
IC50&Target
IC50: 1.2 nM (Src), 1 nM (Abl)
体外研究
Bosutinib (100 nM; 24/48 hours) results in a reduction of S and G2-M phase cells and an increase of cells with a DNA content of less than 2N.
Bosutinib inhibits the proliferation of all three cell lines, with IC50s ranging from 5 nM in the KU812 line to 20 nM for the K562 and MEG-01 cell lines.
Bosutinib (10-500 nM; 4 hours) ablates tyrosine phosphorylation of STAT5 at 25 nM.
Cell Cycle Analysis
Cell Line:
KU812, K562 cells
Concentration:
100 nM
Incubation Time:
24 hours (KU812 cells), 48 hours (K562 cells)
Result:
Resulted in a reduction of S and G2-M phase cells and an increase of cells with a DNA content of less than 2N.
Western Blot Analysis
Cell Line:
K562 cells
Concentration:
10 nM, 25 nM, 50 nM, 100 nM, 500 nM
Incubation Time:
4 hours
Result:
Tyrosine phosphorylation of STAT5 was ablated by 25 nM.
体内研究
Bosutinib (50-150 mg; p.o.; once a day for 5 days) remaines tumor free at 150 mg/kg, whereas at the lower doses, some relapse occurs over a 40-day period in K562 Xenografts in Nude Mice.
Animal Model:
Nude female mice 6–7 weeks of age (K562 xenografts)
Dosage:
50, 75, 100, 150 mg/kg
Administration:
Oral administration, once a day for 5 days
Result:
Remained tumor free at 150 mg/kg, whereas at the lower doses, some relapse occurred over a 40-day period.
分子式
C26H29Cl2N5O3
分子量
530.45
CAS号
380843-75-4
运输条件
Room temperature in continental US; may vary elsewhere.